Last updated on September 2018

A Safety Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Brief description of study

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase and an expansion phase.

Clinical Study Identifier: NCT02571036

Contact Investigators or Research Sites near you

Start Over

Jama Pitman

MD Anderson Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)
Houston, TX United States
  Connect »